- Home
- BIIB vs PAAS Comparison
BIIB vs PAAS Comparison
Compare BIIB & PAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PAAS
- Stock Information
- Founded
- BIIB 1978
- PAAS 1994
- Country
- BIIB United States
- PAAS Canada
- Employees
- BIIB N/A
- PAAS N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PAAS
- Sector
- BIIB Health Care
- PAAS
- Exchange
- BIIB Nasdaq
- PAAS Nasdaq
- Market Cap
- BIIB 18.7B
- PAAS 15.4B
- IPO Year
- BIIB 1991
- PAAS 1995
- Fundamental
- Price
- BIIB $149.17
- PAAS $38.52
- Analyst Decision
- BIIB Buy
- PAAS Strong Buy
- Analyst Count
- BIIB 26
- PAAS 3
- Target Price
- BIIB $182.82
- PAAS $36.67
- AVG Volume (30 Days)
- BIIB 1.8M
- PAAS 7.3M
- Earning Date
- BIIB 10-30-2025
- PAAS 11-04-2025
- Dividend Yield
- BIIB N/A
- PAAS 1.09%
- EPS Growth
- BIIB 31.67
- PAAS N/A
- EPS
- BIIB 10.45
- PAAS 1.44
- Revenue
- BIIB $9,997,000,000.00
- PAAS $3,116,300,000.00
- Revenue This Year
- BIIB $2.00
- PAAS $18.59
- Revenue Next Year
- BIIB N/A
- PAAS $5.59
- P/E Ratio
- BIIB $14.31
- PAAS $26.77
- Revenue Growth
- BIIB 3.36
- PAAS 21.09
- 52 Week Low
- BIIB $110.04
- PAAS $19.80
- 52 Week High
- BIIB $194.13
- PAAS $40.84
- Technical
- Relative Strength Index (RSI)
- BIIB 56.57
- PAAS 59.37
- Support Level
- BIIB $135.39
- PAAS $39.17
- Resistance Level
- BIIB $160.20
- PAAS $40.42
- Average True Range (ATR)
- BIIB 4.43
- PAAS 1.39
- MACD
- BIIB 0.56
- PAAS -0.09
- Stochastic Oscillator
- BIIB 54.23
- PAAS 45.41
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PAAS Pan American Silver Corp.
Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.